To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Trial details
- Registry ID
- NCT05356741
- Phase
- Phase 1, Phase 2